Generex: Antigen Express technology used to detect type 1 diabetes

By Lisa Kerner

Charlotte, N.C., Sept. 19 - Generex Biotechnology Corp. said investigators described the potential of the Antigen Express Ii-Key technologies to accurately diagnose patients with type 1 diabetes at the 42nd Annual Meeting of the European Association for the Study of Diabetes in Copenhagen, Denmark.

By using fragments of the insulin protein modified by proprietary Ii-Key technologies, it was possible to detect T helper immune cells in the peripheral blood of some patients with recent onset type 1 diabetes.

Toronto-based Generex develops drug-delivery systems and technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.